To read the full article sign up for free or sign in.

Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts

April 10, 2026

Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.

BioWorld Financings Cancer CAR T Series D Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Korsana boosts Alzheimer’s work with reverse merger, $380M financing

BioWorld Science

Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...